Skip to main content
UCB logo

UCB — Investor Relations & Filings

Ticker · UCB ISIN · BE0003739530 LEI · 2138008J191VLSGY5A09 BR Manufacturing
Open in API
Filings indexed 2,023 across all filing types
Latest filing 2020-03-13 Earnings Release
Country BE Belgium
Listing BR UCB

About UCB

https://www.ucb.com/

UCB is a global biopharmaceutical company that focuses on creating solutions for people living with severe diseases, primarily in the fields of neurology and immunology. The company's core activities include the research, development, and commercialization of pharmaceutical and biotechnology products. Guided by a patient-centric and science-driven approach, UCB is committed to innovation and sustainability. Through its UCB Ventures arm, it invests in pioneering technologies and companies with the potential to transform patient care. The company also offers personalized support services to patients and healthcare professionals during their treatment journey with a UCB medicine.

Recent filings

Filing Released Lang Actions
Padsevonil update March 13 NL
Earnings Release Classification · 95% confidence The document is a press release dated March 13, 2020, from UCB, a global biopharmaceutical company, announcing the topline results of their Phase 2b clinical trial (ARISE) for the drug padsevonil. It details the study's failure to meet primary endpoints regarding seizure frequency and response rate. This type of announcement, which provides key financial/operational results for a specific period or event (in this case, clinical trial outcomes), aligns best with an Earnings Release (ER) or a general announcement of significant operational news. Since it is not a full annual report (10-K), a comprehensive interim report (IR), or a transcript (CT), and it focuses on the immediate release of key performance indicators (trial results), 'ER' (Earnings Release) is the most appropriate classification, as clinical trial results often serve as the primary 'earnings' or performance metric for biotech/pharma companies when released outside of standard quarterly reporting cycles. It is a direct announcement of results, not a solicitation for votes (DEF 14A/PSI) or a general regulatory filing (RNS). Q1 2020
2020-03-13 Dutch
200311- Disposal of own shares.pdf
Transaction in Own Shares Classification · 99% confidence The document is explicitly titled "Disposal of own shares" and details transactions where UCB SA/NV disposed of its own shares OTC following employee stock option exercises under various Long Term Incentive Plans. This activity directly corresponds to the definition of a company buying back or selling its own shares (share repurchase/issuance). Therefore, the appropriate filing type code is POS (Transaction in Own Shares). The document is a formal announcement, not a short notice about an upcoming report, so the RPA/RNS fallback is not necessary.
2020-03-11 English
200311 - Aliénation d'actions propres.pdf
Share Issue/Capital Change Classification · 99% confidence The document is titled "Aliénation d'actions propres" (Disposal of own shares) and details transactions where UCB SA alienated treasury shares following the exercise of employee stock options. This activity directly relates to the company buying back or issuing its own shares, specifically in the context of employee compensation plans. This aligns perfectly with the definition for 'Transaction in Own Shares' (POS), which covers share repurchase/issuance activities. It is not a general financing update (CAP) but a specific report on share transactions.
2020-03-11 French
200311- Vervreemding van eigen aandelen.pdf
Transaction in Own Shares Classification · 98% confidence The document is titled "Vervreemding van eigen aandelen" (Disposal of own shares) and details transactions where UCB NV disposed of its own shares following option exercises by personnel under various Long-Term Incentive (LTI) plans. This activity directly relates to the company buying back or issuing its own shares, specifically in the context of employee stock options/incentives. This aligns perfectly with the definition for 'Transaction in Own Shares' (POS), which covers share repurchase/issuance. Although it involves employee compensation, the core action is the movement of treasury stock, making POS more specific than DEF 14A (Remuneration Information) or SHA (Share Issue/Capital Change).
2020-03-11 Dutch
200302- Disposal of own shares.pdf
Share Issue/Capital Change Classification · 99% confidence The document is explicitly titled "Disposal of own shares" and details transactions where the company disposed of UCB shares OTC following stock option exercises for employees under various Long Term Incentive Programs. This activity directly corresponds to the definition of a company buying back or selling its own shares (share repurchase/issuance). Therefore, the appropriate filing type is 'Transaction in Own Shares' (POS). The document is a direct announcement of the transaction, not an announcement of a report, so RPA/RNS is not the primary classification.
2020-03-02 English
200302 - Aliénation d'actions propres.pdf
Transaction in Own Shares Classification · 100% confidence The document title is "Aliénation d'actions propres" (Alienation of own shares) and the text details transactions where UCB SA alienated (sold/issued) its own shares following the exercise of options by personnel (LTI plans). This activity directly corresponds to the definition of a company buying back or selling its own shares, which is classified as 'Transaction in Own Shares'. The corresponding code is POS. The document is a formal announcement dated March 2, 2020, detailing transactions from late February 2020.
2020-03-02 French

Browse filings by year

18 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.